Through the Sustainable Markets Initiative (SMI) Health Systems Task Force, we co-led a Power Purchase Agreement (PPA) with peers and suppliers in China.
Through the Sustainable Markets Initiative (SMI) Health Systems Task Force, we co-led a Power Purchase Agreement (PPA) with peers and suppliers in China.
This collaboration among 12 companies will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines.
rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment reversals and total impairment reversals – – ( 1 ) Total impairment reversals ( 33…
Reciprocal relationship from GILD graph: Reciprocal relationship from GLAXF graph: rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment…
Reciprocal relationship from HLNCF graph: Reciprocal relationship from GLAXF graph: Reciprocal relationship from HLNCF graph: Reciprocal relationship from GLAXF graph: Reciprocal relationship from HL…
r 2024 ( 110 ) ( 3,402 ) ( 3,512 ) Total accumulated amortisation and impairment at 31 December 2023 ( 1,382 ) ( 13,197 ) ( 14,579 ) Total accumulated amortisation and impairment at 31 December 2024 …
r 2024 ( 110 ) ( 3,402 ) ( 3,512 ) Total accumulated amortisation and impairment at 31 December 2023 ( 1,382 ) ( 13,197 ) ( 14,579 ) Total accumulated amortisation and impairment at 31 December 2024 …
is recognised when it is highly probable that the sales threshold will be reached. Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occur…
hair of Genetics and Professor of Genetics (& Pathology), Harvard Medical School; Chair of Molecular Biology, Massachusetts General Hospital; Co-Founder and Consultant, Fulcrum Therapeutics; Scientif…
. Our long-acting medicines continue to see increased momentum and are critical to our long-term growth. By the end of 2024 they represented 20% of total HIV sales compared to 16% for 2023 and contri…
n has been recognised. The goodwill represents specific synergies available to GSK from the business combination. The goodwill has been allocated to the Group’s R&D segment. None of the goodwill is e…
hair of Genetics and Professor of Genetics (& Pathology), Harvard Medical School; Chair of Molecular Biology, Massachusetts General Hospital; Co-Founder and Consultant, Fulcrum Therapeutics; Scientif…
st contracts which have been separated from the host contract, are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recogni…
laintiffs’ motion for class certification for 12 March 2025, and a hearing on GSK’s motion for summary judgment for 21 April 2025. Zantac The Group has been named in product liability lawsuits on beh…
GSK plc Debt Obligations
Instrument
Description
Confidence
Evidence
GLAXF-DEBT
Debt stack $25.5B
90%
Market cache reports total debt of $25.5B.
GSK plc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for GSK plc.
GSK plc Ownership
Holder
Name
Confidence
Evidence
GLAXF-OWNER-DZ-BANK-AG-DEUTSCHE-ZENTRAL-GENO
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
90%
13F overlay lists DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main as top holder; 5 tracked holders.
